Sciclone Pharmaceut (SCLN) 10.60 $SCLN Soligenix and

New Post Public Reply Private Reply Replies (0) Message Board

Sep 24, 2016 at 5:03 AM

Sciclone Pharmaceut (SCLN) 10.60 $SCLN

Soligenix and SciClone Establish Regional Licensing Agreement for SGX942, a Novel Product Candidate for Oral Mucositis
PR Newswire - Mon Sep 12, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, and SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN), a US-based China-focused specialty pharmaceutical company, announced today that the companies have entered into an exclusive license agreement granting rights to SciClone to develop, promote, market, distribute and sell SGX942 (dusquetide), a novel, first-in-class therapy being developed for the treatment of oral mucositis in patients with head and neck cancer. The licensing agreement includes the People's Republic of China, including Hong Kong and Macau, as well as Taiwan, South Korea and Vietnam (the "Territory"

. This exclusive agreement builds on an existing collaboration between the two companies, in which SciClone provided its complete oral mucositis clinical and regulatory data library to Soligenix in exchange for certain, previously undisclosed, commercialization rights to SGX942 in the Greater China market.
SCLN: 10.60 (-0.06)

SciClone To Present At Two Investor Conferences In September 2016
PR Newswire - Thu Sep 01, 3:05PM CDT
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company will present a corporate overview and business update at two investor conferences in September 2016.
SCLN: 10.60 (-0.06)

SciClone Reports Second Quarter 2016 Financial Results
PR Newswire - Tue Aug 09, 3:05PM CDT
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter ended June 30, 2016.
SCLN: 10.60 (-0.06)

Sciclone Pharmaceuticals Has Returned 70.9% Since SmarTrend Recommendation (SCLN)
Comtex SmarTrend(R) - Fri Jun 10, 12:40PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 7 months, Sciclone Pharmaceuticals has returned 70.93% as of today's recent price of $13.63.
SCLN: 10.60 (-0.06)

Shares of SCLN Up 74.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 03, 12:11AM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 7 months, Sciclone Pharmaceuticals has returned 74.17% as of today's recent price of $13.89.
SCLN: 10.60 (-0.06)

Sciclone Pharmaceuticals Shares Up 62.9% Since SmarTrend's Buy Recommendation (SCLN)
Comtex SmarTrend(R) - Thu May 26, 12:40PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 7 months, Sciclone Pharmaceuticals has returned 62.88% as of today's recent price of $12.99.
SCLN: 10.60 (-0.06)

AWS Morning Technical Breakdown Highlights: Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma
ACCESSWIRE - Mon May 23, 8:16AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma.
NVO: 44.88 (-0.69), SCMP: 13.23 (-0.15), SCLN: 10.60 (-0.06), BIOD: 0.45 (+0.03)

Uptrend Call Working As Sciclone Pharmaceuticals Stock Rises 64.4% (SCLN)
Comtex SmarTrend(R) - Wed May 11, 12:42PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 6 months, Sciclone Pharmaceuticals has returned 64.39% as of today's recent price of $13.11.
SCLN: 10.60 (-0.06)

SciClone Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 5:00AM CDT
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter ended March 31, 2016.
SCLN: 10.60 (-0.06)

SciClone Pharmaceuticals To Report First Quarter 2016 Financial Results On May 10, 2016
PR Newswire - Mon Apr 25, 5:00AM CDT
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the first quarter 2016 on Tuesday, May 10, 2016. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET (5:30 am PT) that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Wilson W. Cheung, Senior Vice President and CFO.
SCLN: 10.60 (-0.06)

Shares of SCLN Up 62.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 19, 12:15AM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 5 months, Sciclone Pharmaceuticals has returned 62.51% as of today's recent price of $12.96.
SCLN: 10.60 (-0.06)

SciClone Announces Final Resolution With The Securities And Exchange Commission And The Department Of Justice
PR Newswire - Thu Feb 04, 4:02PM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) (the "Company"

today announced it has entered into a settlement agreement with the United States Securities and Exchange Commission (SEC) fully resolving the SEC's investigation into possible violations of the Foreign Corrupt Practices Act (FCPA). Under the terms of the settlement agreement, SciClone has agreed to pay a total of $12.8 million, including disgorgement, pre-judgment interest and a penalty. This payment is in line with the charges the Company previously recorded and disclosed in its Form 10-Q filed with the SEC on August 10, 2015. As part of the agreement, the Company neither admits nor denies it engaged in any wrongdoing. The Department of Justice (DOJ) has also completed its related investigation and has declined to pursue any action.
SCLN: 10.60 (-0.06)

SciClone To Present At BIO CEO & Investor Conference On February 9, 2016
PR Newswire - Wed Jan 27, 5:00AM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the 18th Annual BIO CEO & Investor Conference at 8:30 am ET on Tuesday, February 9, 2016, at the Waldorf Astoria Hotel in New York City.
SCLN: 10.60 (-0.06)

Soligenix Provides 2016 Business Outlook
PR Newswire - Tue Jan 26, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its 2016 business outlook. This outlook is intended to provide Soligenix investors with a summary of the 2015 accomplishments as well as the anticipated activities and milestones for the coming year.
SCLN: 10.60 (-0.06)

SciClone Announces Preliminary 2015 Revenue
PR Newswire - Mon Jan 11, 5:00AM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced its preliminary 2015 revenue results, and that it has achieved its revenue expectations for 2015.
SCLN: 10.60 (-0.06)

16.1% Return Seen to Date on SmarTrend Sciclone Pharmaceuticals Call (SCLN)
Comtex SmarTrend(R) - Thu Dec 24, 10:33AM CST
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 2 month, Sciclone Pharmaceuticals has returned 16.11% as of today's recent price of $9.26.
SCLN: 10.60 (-0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AppLovin Faces Serious Investor Lawsuit Deadline

Investors' Trust Shaken: The AppLovin Controversy Well, what do we have here? Another day, another hefty lawsuit coming down the pike. The spotlight’s on AppLovin Corporation (NASDAQ: APP), where the Hagens Berman law sharks are sniffing blood in the water over what they claim are federal securities law violations. The core of this legal storm swirls around AppLovin's...

Partner Joins Yardi ICN, Boosting Data Quality for Clients

Strategic Alliances in Real Estate Data When Partner Engineering and Science, Inc. says they're hooking up with the Yardi Independent Consultant Network (ICN), that's not just some boardroom handshake. It's a play that could shake up data services in the real estate game. Look, there's plenty of chatter about digitizing property management, but without killer data, those...

AI-Driven Software Growth Faces Profitability Hurdles

AI and Growth: A Tale of Two Strategies Is AI the superhero we’ve been waiting for, or just another fad? The KeyBanc Capital Markets' 2026 AI x Software Benchmark throws more questions into the ring than it answers. This benchmark isn't just numbers on a page; it's a pulse check on how AI is reshaping the software landscape. Seeing AI-native firms grow at a dizzying 34%...

DEEPBLUE's Panelized Systems Target Low-Rise Markets

Changing the Game in Low-Rise Construction Been around the block a few times and seen all sorts of hype in this industry, but what DEEPBLUE SMARTHOUSE is pushing sounds more like evolution than revolution for low-rise builds. They're leaning into this panelized building system like a boxer on the ropes—that's their strategy to keep things steady and predictable. The...

Black Bayou Kicks Off Major Gas Storage Build in Louisiana

Breaking Ground on a Massive Energy Undertaking Well, folks, Black Bayou's finally breaking ground on their colossal gas storage project in Cameron Parish, Louisiana. They're not just playing around—this thing's set to be a juggernaut, with an imposing 44.4 Bcf of working gas capacity nestled right on top of the Black Bayou salt dome. Talk about marking territory, huh?...

Decoding Arrest: Steps from Arraignment to Trial

Someone lands in handcuffs, and it's the start of a winding road through the justice system. We're talking about the stages you gotta navigate, explained by Criminal Law Attorney Tangi Carter. If you're anywhere near Hattiesburg, Mississippi, or quite frankly, have any eye on legal matters in your backyard, you know having a roadmap is pure gold. Arraignment: The...

Global Energy Storage Colloquium Sparks Collaboration

Setting the Stage for Energy Storage Breakthroughs Imagine a room bustling with brainpower, brimming with the promise of cleaner, more efficient energy. That's the scene at the inaugural Global Energy Storage Colloquium in Xiamen, where top-tier experts from all corners gathered to uncover what's next for energy storage. We're not just talking new gadgets but giant leaps...

Cemig and Huawei's Bold Network Leap: Power Up

Taking the Leap in Brazil's Power Grid In Brazil, energy distribution's a whole different beast, and boy, is it complicated! Cemig found out the hard way that relying on public networks was a risky bet. Consistently bad. With a measly 50% coverage in Brazil's vast lands, you're looking at a communications nightmare, especially in the back of beyond where grid faults could...

SciGround Launches: A Game-Changer in Research Verification

Unshackling Research Verification from the Model Folks, here's the big one—Licklider, Inc. from Tokyo lobbed a curveball with their new player in town: SciGround. This platform takes the reins on mathematically verifying AI-driven research, which is something you'll want to keep an eye on if you're at all interested in AI or research replication. Why SciGround Gets My...

Choosing Expert European Auto Repair: Key Insights

The Perks of Specialist Knowledge Ever get the feeling your local auto shop doesn't always cut it when your sleek BMW or classy Mercedes needs a tweak? You're not alone. Specifically, for those driving around Alpharetta, European vehicles demand not just routine check-ups but specialist hands. Much like how you wouldn't hand your luxury timepiece to the shop down the...